FDA Inspection 1150528 — Geisinger Institutional Review Board
The FDA completed an inspection of Geisinger Institutional Review Board on August 6, 2021 in Danville, PA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- August 6, 2021
- Fiscal Year
- 2021
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Danville, PA (United States)
Additional Details
IRB